Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens

References

• Rubin I, Yarden Y The basic biology of HER2. Ann Oncol. 2001;12 1:S3–8 Accessed 1st January 2022.
   PubMedGoogle Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007 Oct 4;2645:6469–6487.
   PubMedGoogle Scholar
• Appert-Collin A, Hubert P, Crémel G, et al. Role of ErbB receptors in cancer cell migration and invasion. Front Pharmacol. 2015 Nov 24;6:283.
   PubMedGoogle Scholar
• Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015 Mar;34(1):157–164.
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020 Jan;17(1):33–48.
   PubMed Web of Science ®Google Scholar
• Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002 Jun 25;9913:8880–8885.
   PubMedGoogle Scholar
• Peckys DB, Korf U, de Jonge N. Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopy. Sci Adv. 2015 Jul 17;16:e1500165.
   PubMedGoogle Scholar
• Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009 Apr;14(4):320–368.
   PubMed Web of Science ®Google Scholar
• Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985 Dec 6; 2304730:1132–1139.
   PubMedGoogle Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985 Sep 6;2294717:974–976
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Jimenez RE, Wallis T, Tabasczka P, et al. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000 Jan;13(1):37–45.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018 Jul 10;3620:2105–2122.
   PubMedGoogle Scholar
• Gradishar WJ, Moran MS, Abraham J, et al. National comprehensive cancer network. Breast Cancer (version2.2022). 2022. Breast Cancer (version2.2022): www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Acessed Jan 1st 2022.
   Google Scholar
• FDA Approval Letter. Herceptin. 1998 Sept 25. At: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/trasgen092598L.pdf Accessed 2022 Jan 1st.
   Google Scholar
• Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug;16(8):2659–2671.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;35316:1673–1684.
   PubMedGoogle Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin adjuvant (HERA) trial study team. trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;35316:1659–1672.
   PubMedGoogle Scholar
• Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94(1):S5.
   Google Scholar
• Untch M, Gelber RD, Jackisch C, et al. HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008 Jun;19(6):1090–1096.
   PubMedGoogle Scholar
• US Food and Drug Administration. HERCEPTIN® (trastuzumab). Prescribing Information. 2022. Available at: https://www.gene.com/download/pdf/herceptin_prescribing.pdf. Accessed 2022 Jan 1st.
   Google Scholar
• Hudis CA. Trastuzumab — mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;3571:39–51.
   PubMedGoogle Scholar
• Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med. 2002 Oct;8(10):1145–1152.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan K-H, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004 Aug;6(2):117–127.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–446.
   PubMed Web of Science ®Google Scholar
• Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010 Aug 15;1616:4226–4235.
   PubMedGoogle Scholar
• Green AR, Barros FFT, Abdel-Fatah TMA, et al. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat. 2014 May;145(1):33–44.
   PubMed Web of Science ®Google Scholar
• Dave B, Migliaccio I, Gutierrez MC, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2–Overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10;292:166–173.
   PubMedGoogle Scholar
• Gallardo A, Lerma E, Escuin D, et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 2012 Apr 10;1068:1367–1373.
   PubMedGoogle Scholar
• Minuti G, Cappuzzo F, Duchnowska R, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 2012 Aug 21;1075:793–799.
   PubMedGoogle Scholar
• Scaltriti M, Eichhorn PJ, Cortés J, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients. Proc Natl Acad Sci U S A. 2011 Mar 1;1089:3761–3766.
   PubMedGoogle Scholar
• Zhang S, Huang W-C, Li P, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011 Apr;17(4):461–469.
   PubMed Web of Science ®Google Scholar
• Menyhárt O, Santarpia L, Győrffy B A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer. Curr Cancer Drug Targets. 2015;15(8):665–683.
   PubMedGoogle Scholar
• Ewer MS, Lippman SM Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005 May 1;23(13):2900–2902.
   PubMedGoogle Scholar
• Curigliano G, Lenihan D, Fradley M, et al.; ESMO Guidelines Committee. Electronic address: management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020 Feb;31(2):171–190. PMID: 31959335; PMCID: PMC8019325.
   PubMed Web of Science ®Google Scholar
• Marti JLG, Hyder T, Nasrazadani A, et al. The evolving landscape of HER2-directed breast cancer therapy. Curr Treat Options Oncol. 2020 Aug 7;21(10):82.
   PubMedGoogle Scholar
• Wang C, Chen J, Xu X, et al. Dual HER2 Blockade in neoadjuvant treatment of HER2+ breast cancer: a meta-analysis and review. Technol Cancer Res Treat. Jan-Dec 2020;19:1533033820960721.
   Web of Science ®Google Scholar
• US Food and Drug Administration. PERJETA® (pertuzumab). Prescribing Information. 2022 Accessed 1st January 2022. Available at: https://www.gene.com/download/pdf/perjeta_prescribing.pdf
   Google Scholar
• Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 1990 Mar 1;50(5):1550–1558.
   PubMedGoogle Scholar
• Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10;23(11):2534–2543.
   PubMed Web of Science ®Google Scholar
• Attard G, Kitzen J, Blagden SP, et al., A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer. 97(10):1338–1343. 2007 Nov 19 .
   PubMedGoogle Scholar
• Albanell J, Montagut C, Jones ET, et al., A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 14(9):2726–2731. 2008 May 1.
   PubMedGoogle Scholar
• Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol. 2009 Apr;39(4):260–266.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Fumoleau P, Verma S. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol. 2008;26(15):1026.
   Google Scholar
• Baselga J, Gelmon KA, Verma S, et al., Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 28(7):1138–1144. 2010 Mar 1 .
   PubMedGoogle Scholar
• Baselga J, Cortés J, Kim SB, et al., Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 366(2):109–119. 2012 Jan 12.
   PubMedGoogle Scholar
• Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519–530.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25–32.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–2284.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al.; APHINITY Steering committee and investigators. adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122–131. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. KADCYLA® (ado-trastuzumab emtansine) Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf. Accessed January 1st, 2022.
   Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783–1791 Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442.
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017 Jun;18(6):743–754.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Huang CS, Mano MS, et al., KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 380(7):617–628. 2019 Feb 14.
   PubMedGoogle Scholar
• Tolaney SM, Tayob N, Dang C, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021 Jul 20;39(21):2375–2385.
   PubMedGoogle Scholar
• Modi S, Saura C, Yamashita T, et al. DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610–621.
   PubMedGoogle Scholar
• Cortés J, Kim SB, Chung WP, et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. 2021 Sep 1;32:LBA1.
   Google Scholar
• a phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (t-dxd) versus trastuzumab emtansine (t-dm1) in participants with high-risk HER2-positive primary breast cancer who have residual invasive DISEASE IN BREAST or axillary lymph nodes following neoadjuvant therapy (DESTINY-breast05) Accessed 31st January 2022 https://clinicaltrials.gov/ct2/show/NCT04622319
   Google Scholar
• Manich CS, O’Shaughnessy J, Aftimos PG, et al. LBA15 Primary outcome of the phase III SYD985. 002/TULIP trial comparing [vic-] trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol. 2021 Sep 1;32:S1288. Abstract: LBA15.
   Google Scholar
• Spector NL, Xia W, Burris H 3rd, et al., Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 23(11):2502–2512. 2005 Apr 10.
   PubMedGoogle Scholar
• Konecny GE, Pegram MD, Venkatesan N, et al., Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66(3):1630–1639. 2006 Feb 1.
   PubMedGoogle Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733–2743. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec;112(3):533–543.
   PubMed Web of Science ®Google Scholar
• Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–592.
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):367–377.
   PubMed Web of Science ®Google Scholar
• Chan A, Moy B, Mansi J, et al.; ExteNET Study Group. Final efficacy results of neratinib in her2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2021 Feb;21(1):80–91.e7.
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, Feng YH, et al., NALA investigators. neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA Trial. J Clin Oncol. 38(27):3138–3149. 2020 Sep 20.
   PubMedGoogle Scholar
• Murthy RK, Loi S, Okines A, et al. Trastuzumab, and Capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020 Feb 13;382(7):597–609. Epub 2019 Dec 11. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586.
   PubMedGoogle Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 1;27(34):5700–5706.
   PubMedGoogle Scholar
• Curigliano G, Viale G, Bagnardi V, et al., Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 27(34):5693–5699. 2009 Dec 1.
   PubMedGoogle Scholar
• Slamon D, Eiermann W, Robert N, et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273–1283.
   PubMedGoogle Scholar
• Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013 Oct;14(11):1121–1128.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 8;372(2):134–141. Erratum in: N Engl J Med. 2015 Nov 12;373(20):1989.
   PubMed Web of Science ®Google Scholar
• Bellon JR, Guo H, Barry WT, et al. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul;176(2):303–310.
   PubMed Web of Science ®Google Scholar
• Diker O, Aktas BY, Ak R, et al. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience. Future Oncol. 2022 Jan;18(3):323–331.
   PubMedGoogle Scholar
• Amiri-Kordestani L, Xie D, Tolaney SM, et al. A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials. Ann Oncol. 2020 Dec;31(12):1704–1708.
   PubMedGoogle Scholar
• a randomized phase ii trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for stage I HER2-positive breast cancer (ATEMPT 2.0) Accessed 2022 Jan 1st. https://clinicaltrials.gov/ct2/show/NCT04893109
   Google Scholar
• Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10;32(20):2142–2150.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Capra AM, Cp Q Jr, et al., Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 32(20):2151–2158. 2014 Jul 10.
   PubMedGoogle Scholar
• Parsons BM, Uprety D, Smith AL, et al. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer. J Natl Compr Canc Netw. 2018 Nov;16(11):1311–1320.
   PubMedGoogle Scholar
• Cao L, Shenk R, Stabellini N, et al. Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis. Breast Cancer Res Treat. 2021 Oct 16.
   Google Scholar
• Rodrigues MJ, Peron J, Frénel JS, et al. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol. 2013 Apr;24(4):916–924.
   PubMed Web of Science ®Google Scholar
• Si J, Guo R, Pan H, et al. Multiple Microinvasion Foci in Ductal Carcinoma In Situ Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome. Front Oncol. 2020 Dec 3;10:607502.
   PubMedGoogle Scholar
• Templeton A, Ocaña A, Seruga B, et al. Management of small HER2 overexpressing tumours. Breast Cancer Res Treat. 2012 Nov;136(1):289–293.
   PubMedGoogle Scholar
• McArthur HL, Mahoney KM, Morris PG, et al., Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 117(24):5461–5468. 2011 Dec 15.
   PubMedGoogle Scholar
• Kiess AP, McArthur HL, Mahoney K, et al., Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer. 118(8):1982–1988. 2012 Apr 15.
   PubMedGoogle Scholar
• He X, Ji J, Tian M, et al., Long-term survival analysis of adjuvant chemotherapy with or without trastuzumab in patients with T1, node-negative HER2-positive breast cancer. Clin Cancer Res. 25(24):7388–7395. 2019 Dec 15 .
   PubMedGoogle Scholar
• Hudis CA, Barlow WE, Costantino JP, et al., Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 25(15):2127–2132. 2007 May 20.
   PubMedGoogle Scholar
• Tolaney SM, Garrett-Mayer E, White J, et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol. 2021 Aug 20;39(24):2720–2731.
   PubMedGoogle Scholar
• Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (definition for the assessment of time-to-event endpoints in CANcer trials). Ann Oncol. 2015 Dec;26(12):2505–2506. Epub 2015 Oct 13. Erratum for: Ann Oncol. 2015 May;26(5):873-9.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry, 2019 Accessed 1st January 2022. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics
   Google Scholar
• Harbeck N, Schneeweiss A, Thuss-Patience P, et al. Neoadjuvant and adjuvant end-points in health technology assessment in oncology. Eur J Cancer. Apr 2021;147:40–50.
   PubMedGoogle Scholar
• Bartlett JM, McConkey CC, Munro AF, et al., Predicting anthracycline benefit: TOP2A and CEP17-Not Only but also. J Clin Oncol. 33(15):1680–1687. 2015 May 20 .
   PubMedGoogle Scholar
• Zhong W, Yang Y, Zhang A, et al. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer. Breast Cancer. 2020 Nov;27(6):1147–1157.
   PubMedGoogle Scholar
• Ibrahim EM, Kazkaz GA, Al-Mansour MM, et al. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis. Breast Cancer Res Treat. 2015 Aug;152(3):463–476.
   PubMedGoogle Scholar
• Cardoso F, Van’t Veer Lj, Bogaerts J, et al., MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 375(8):717–729. 2016 Aug 25 .
   PubMedGoogle Scholar
• Single-arm A, Multicentre, Pragmatic Trial Evaluating 6-months of HER2-targeted Therapy in Patients with HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy (REaCT-HER TIME). Accessed Jan 1st, 2022. https://clinicaltrials.gov/ct2/show/NCT04928261?term=her2%2C±trastuzumab&recrs=abd&type=Intr&cond=Breast±Cancer&phase=123&draw=2&rank=69. Accessed Jan 1st, 2022
   Google Scholar